Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suramin sodium - Kuzani Pharmaceuticals

Next Previous
Drug Profile

Suramin sodium - Kuzani Pharmaceuticals

Alternative Names: KZ-101

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kuzani Pharmaceuticals
  • Class Antiprotozoals; Behavioural disorder therapies; Naphthalenesulfonates
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pervasive child development disorders

Most Recent Events

  • 09 Apr 2025 Phase-I clinical trials in Pervasive child development disorders (In children, In adolescents) in USA (IV) (NCT06866275)
  • 10 Mar 2025 Children's Hospital of Orange County in collaboration with Kuzani Pharmaceuticals plans the phase II STAT-2A trial for Pervasive child development disorders (In Children) (IV, Infusion) (NCT06866275)
  • 10 Mar 2025 Preclinical trials in Pervasive child development disorders in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top